ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
16.44
-0.64 (-3.72%)
Mar 31, 2025, 9:47 AM EDT - Market open

Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage.

The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS.

The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997.

ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals logo
Country United States
Founded 1993
IPO Date May 27, 2004
Industry Biotechnology
Sector Healthcare
Employees 654
CEO Catherine Owen Adams

Contact Details

Address:
12830 El Camino Real, Suite 400
San Diego, California 92130
United States
Phone 858 558 2871
Website acadia.com

Stock Details

Ticker Symbol ACAD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001070494
CUSIP Number 004225108
ISIN Number US0042251084
Employer ID 06-1376651
SIC Code 2834

Key Executives

Name Position
Catherine E. Owen Adams Chief Executive Officer and Director
Mark C. Schneyer Executive Vice President and Chief Financial Officer
Stephen R. Davis J.D. Consultant
Dr. Elizabeth H.Z. Thompson Ph.D. Head of Research and Development
Jennifer J. Rhodes J.D. Chief Legal Officer and Secretary
Rob Ackles Chief People Officer
James K. Kihara Senior Vice President of Finance
Dr. Kevin R. Oliver Ph.D. Chief Business Officer
Thomas Andrew Garner Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 6, 2025 144 Filing
Feb 27, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 7, 2025 SCHEDULE 13G/A Filing
Dec 11, 2024 8-K Current Report
Nov 20, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report